Research and Markets: Key Findings from Treatment Algorithms: Schizophrenia

DUBLIN--(BUSINESS WIRE)-- Research and Markets ( has announced the addition of Decision Resources, Inc's new report "Key Findings from Treatment Algorithms: Schizophrenia" to their offering.

Since the introduction of the first atypical antipsychotic, clozapine, to the U.S. market in 1990, the more-favorable tolerability of atypical antipsychotics (in particular, a lower risk of extrapyramidal symptoms) has made this drug class the cornerstone of schizophrenia treatment. As of June 2011, ten different atypical antipsychotic molecules have launched in the United States, and in 2012, three oral atypicals (risperidone [Janssen's Risperdal, generics], olanzapine [Eli Lilly's Zyprexa], and quetiapine [AstraZeneca's Seroquel]) will be generically available. Emerging antipsychotics will face an uphill battle to differentiate themselves in this crowded and increasingly genericized market.

Key Topics Covered:

1. Background

- Publication Update

- Report Contents and Features

- Current Practice Guidelines

- Key U.S. Market Events Influencing Treatment Selection

2. Key Findings for Newly Diagnosed Patients

- Executive Summary

- Graphical Views

3. Key Findings for Recently Treated Patients

- Executive Summary

- Graphical Views

4. Key Findings by Product

- Zyprexa

- Seroquel and Seroquel XR

- Abilify

- Geodon

- Invega and Invega Sustenna

- Risperdal Consta

5. Appendix: Methodology

For more information visit

Source: Decision Resources, Inc

Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices, Central Nervous System

Source: Research and Markets